Sepracor-Looks very promising Message Board

6/17/2003 12:13:51 PM

Biomaven, I think a 20-25% market share is achievable over 3 or 4 years. Compared to when X was released SEPR has the advantage of an established and much larger sales force and an existing version of the product on the market. The pricing of the X-MDI will also be substantially higher than racemic Albuterol resulting in a much higher share of the revenues.

V1